SCHEDULE: Adage Capital Discloses 9.99% Stake in Milestone Pharma

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 9.99% beneficial ownership stake in Milestone Pharmaceuticals Inc. as of September 30, 2025.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in Milestone Pharmaceuticals Inc.
• The Reporting Persons collectively beneficially own 8,659,064 Common Shares of Milestone Pharmaceuticals Inc., representing 9.99% of the class.
• This ownership includes 1,683,064 Common Shares issuable upon the exercise of warrants.
• The percentage of class is calculated based on 84,994,261 Common Shares outstanding as of August 12, 2025, as reported in the Company's Form 10-Q for the quarter ended June 30, 2025.
• The Reporting Persons hold shared voting power and shared dispositive power over all 8,659,064 shares.
• The filing is made under Rule 13d-1(b), indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant institutional investment by a reputable firm, which is generally a positive signal for the company's perceived value and stability. However, it provides no operational or financial performance details, limiting a higher sentiment score.

Positives

• A significant institutional investor, Adage Capital Management, L.P., has taken a substantial 9.99% stake, potentially signaling confidence in Milestone Pharmaceuticals Inc.'s long-term prospects.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business, without the intent to change or influence control, suggesting a passive, long-term investment perspective.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Milestone Pharmaceuticals Inc.'s future performance, strategic direction, or operational outlook. It solely reports a change in beneficial ownership by an institutional investor.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This Schedule 13G filing highlights a significant passive investment by a major institutional asset manager in a pharmaceutical company. Such disclosures are common in the biotech and pharmaceutical sectors, where institutional investors frequently take substantial positions in companies perceived to have strong potential. The investment by Adage Capital Management, L.P. suggests a belief in the long-term value proposition of Milestone Pharmaceuticals Inc. within the competitive pharmaceutical industry.

Comparison to Industry Standards

• Adage Capital Management, L.P. is a well-regarded institutional investor, and its 9.99% stake represents a substantial position, often interpreted as a vote of confidence in the company's prospects.
• For a pharmaceutical company like Milestone Pharmaceuticals Inc., attracting significant institutional investment is generally a positive indicator, aligning with industry trends where capital flows towards companies with promising pipelines or market opportunities.
• The passive nature of this investment, as indicated by the Rule 13d-1(b) filing, is standard for institutional investors who do not seek to influence corporate control, distinguishing it from more activist investor filings (e.g., Schedule 13D).

Stakeholder Impact

• Shareholders: Existing shareholders may view the significant institutional investment as a positive signal, potentially increasing confidence and demand for the stock.
• Management: The investment by a reputable firm could be seen as validation of the company's strategy and potential, potentially boosting morale and market perception.

Next Steps

• Milestone Pharmaceuticals Inc. will continue its operations and report financial results as per SEC regulations.
• Adage Capital Management, L.P. will continue to hold or adjust its position in Milestone Pharmaceuticals Inc., with future Schedule 13G/A amendments filed if beneficial ownership changes significantly.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant passive investment by Adage Capital Management, L.P., a reputable institutional investor, in Milestone Pharmaceuticals Inc. While a large institutional stake can be a positive signal, the filing itself does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily reflects an investor's position. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting further operational and financial disclosures from Milestone Pharmaceuticals Inc. to assess its fundamental value and future prospects.

Keywords

Milestone Pharmaceuticals, Adage Capital Management, Robert Atchinson, Phillip Gross, Schedule 13G, beneficial ownership, common shares, institutional investment, warrants, SEC filing